Table 4. Neutralization profiles of purified IgM mAbs selected from cloned hybridoma lines.
| SVAd |
92UG037 |
MN |
SF162 |
6535 |
BG1168 |
ZM14654 |
DU156 |
|
|---|---|---|---|---|---|---|---|---|
| Clone ID | IC50c | IC50 | IC50 | IC50 | IC50 | IC50 | IC50 | IC50 |
| 2F5a | >50 | 0.18 | <0.023 | 2.01 | 9.83 | 2.13 | >50 | >50 |
| 4E10a | >50 | 0.11 | <0.023 | 2.50 | 0.94 | 3.54 | 0.38 | 0.21 |
| V3-1.4a | >50 | 0.09 | <0.023 | 1.92 | 1.56 | 1.25 | 2.79 | >50 |
| AID 3G11b | >50 | >50 | >50 | >50 | >50 | >50 | >50 | >50 |
| 13H11b | >50 | >50 | >50 | >50 | >50 | >50 | >50 | >50 |
| 2F5-V101-282 CL1 | >50 | 0.23 | <0.011 | 3.07 | 1.38 | 2.85 | 2.56 | >25 |
| 2F5-V101-9 CL1 | >25 | 0.05 | 0.01 | 3.15 | 1.26 | 1.58 | 1.83 | >25 |
| 2F5-V101 136 CL1 | >25 | 0.12 | 0.03 | 4.40 | 1.54 | 2.19 | 1.75 | 12.44 |
| 2F5-V101-175 CL1 | >25 | 0.13 | 0.07 | 3.87 | 1.63 | 2.84 | 1.99 | >25 |
| 2F5-V101-256 CL1 | >25 | 0.10 | <0.011 | 3.16 | 1.05 | 1.67 | 1.41 | >25 |
| 4E10-V2-5 CL1 | >50 | 0.98 | 0.04 | 10.31 | 2.46 | 7.81 | 0.57 | 0.29 |
| 4E10-V2-98 CL1 | >50 | 0.65 | 0.07 | 9.50 | 3.90 | 13.41 | 0.57 | 0.28 |
| 4E10-V2-6 CL4 | >50 | 0.69 | 0.15 | 11.87 | 4.03 | 15.71 | 1.58 | 0.49 |
| 4E10-V2-3 CL1 | >25 | 0.43 | 0.21 | 8.88 | 0.46 | 4.05 | 0.12 | 0.09 |
| 4E10-V3-1 CL1 | >25 | 0.31 | 0.19 | 5.37 | 0.23 | 2.23 | 0.10 | 0.03 |
| 4E10-V3-6 CL1 | >25 | 0.40 | 0.10 | 7.19 | 0.50 | 3.48 | 0.10 | 0.05 |
| 4E10-V2-49 CLe | >50 | >50 | >50 | >50 | >50 | >50 | >50 | >50 |
| 4E10-V2-50 CLe | >50 | >50 | >50 | >50 | >50 | >50 | >50 | >50 |
a
Recombinant human 2F5, 4E10 and mouse mAb V3-1.4 were used as positive control antibodies.
b
Mouse mAbs AID 3G11 and 13H11 were used as negative control.
c
Shown are 50% neutralization concentrations (IC50) of affinity-purified mAbs required to neutralize each HIV-1 isolate listed in the TZM-bl cell assay.
d
SVA was used as a negative control virus.
e
Clones underwent VH replacement.